J&J’s Breakthrough: Teclistamab + Daratumumab Smashes PFS Records in Multiple Myeloma

This video analyzes the groundbreaking results from the MajesTEC-3 trial, featuring the combination of Teclistamab (Tec) and Daratumumab (Dara). This doublet regimen is redefining expectations for Relapsed/Refractory Multiple Myeloma (RRMM) with efficacy levels typically reserved for frontline therapy.

Clinical Highlights:
* Unprecedented Risk Reduction: The trial demonstrated a massive 83% reduction in the risk of disease progression or death, with a Hazard Ratio of 0.17.
* Superior Survival Rates: At the 36-month mark, the Overall Survival (OS) rate reached 83.3% for the treatment arm, compared to 65% for the standard of care.
* Deep Clinical Response: The combination achieved significantly higher rates of Complete Response (CR) and MRD negativity at 10^-6.
* Manageable Safety Profile: Safety was maintained through Step-Up Dosing (SUD) to manage Cytokine Release Syndrome (CRS) and immunoglobulin support to mitigate infection risks.

Bispecifics vs. CAR-T:
We discuss why this off-the-shelf subcutaneous therapy may be utilized earlier than CAR-T. Due to its ease of administration and lower cost, it allows community oncologists to provide advanced immunotherapy without the need for specialized CAR-T facilities.

About this Video:
Summary of clinical data, trial design, and the practice-changing potential of J&J's newest immunotherapy doublet in the treatment of incurable blood cancers.

#MultipleMyeloma #Biotech #Immunotherapy #CancerResearch #JNJ #ClinicalTrials #MajesTEC3 #Oncology #Hematology #Teclistamab #Daratumumab #CancerTreatment #MedicalNews #BloodCancer #pharma

BioSpark Group is a non-profit corporation registered in Massachusetts in the United States. The purpose of BioSpark Group is to establish a biotechnology ecosystem with a collaborative and supportive scholar network, promote leadership and entrepreneurship, and facilitate scientific translation. http://biospark.org/

Видео J&J’s Breakthrough: Teclistamab + Daratumumab Smashes PFS Records in Multiple Myeloma канала BioSpark Group